Used in research as a potent and selective inhibitor of the c-Met kinase, AZD3264 demonstrates potential in targeting tumor growth and cancer progression, particularly in cancers driven by c-Met pathway dysregulation. It is primarily investigated for its antitumor activity in non-small cell lung cancer and other solid tumors. Its high selectivity allows for targeted therapy with reduced off-target effects, making it a candidate for development in precision oncology. Studies focus on its pharmacokinetic profile and efficacy in inhibiting hepatocyte growth factor-mediated signaling, which plays a key role in cell proliferation, survival, and metastasis.